Genotype-Matched Blood Transfusion for Sickle Cell Disease
Trial Summary
What is the purpose of this trial?
This is a pilot study to evaluate the feasibility and safety of providing RH genotype matched D+ Red Blood Cells (RBCs) to chronically transfused patients with sickle cell disease (SCD) who type D+ but have formed anti-D and are currently transfused with D- RBC (Red Blood Cell) units.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the idea that Genotype-Matched Blood Transfusion for Sickle Cell Disease is an effective treatment?
The available research shows that Genotype-Matched Blood Transfusion can help reduce complications in sickle cell disease patients. One study found that patients with partial D antigens who received genotype-matched transfusions had fewer issues with anti-D antibodies, which can cause problems with blood transfusions. Another study highlighted that using genotype-matched blood can lower the risk of Rh immunization, a common issue in sickle cell patients receiving transfusions. This suggests that matching the blood more closely to the patient's genetic makeup can improve the effectiveness and safety of transfusions compared to traditional methods.12345
What safety data exists for genotype-matched blood transfusion in sickle cell disease?
The safety data for genotype-matched blood transfusion in sickle cell disease suggests that RH genotype matching may reduce Rh alloimmunization, which is a common issue despite serologic Rh-matched transfusions. Studies indicate that patients with partial D antigens may benefit from RH genotype-matched transfusions to prevent anti-D formation. RH genotype matching is feasible and could optimize the use of minority donor blood, although it requires more resources and donor recruitment. High-resolution RH genotyping has shown that variant alleles contribute to Rh alloimmunization, and matching based on RH genotype could potentially reduce this risk. However, the feasibility and cost of implementing widespread RH genotyping remain challenges.12456
Is the treatment D+ RH genotype matched red cell units a promising treatment for sickle cell disease?
Yes, D+ RH genotype matched red cell units are promising for sickle cell disease because they can help prevent the development of harmful antibodies during blood transfusions. This matching can improve the use of valuable blood donations, reduce the risk of immune reactions, and ensure better compatibility between donors and patients.12347
Research Team
Stella Chou, MD
Principal Investigator
Children's Hospital of Philadelphia
Eligibility Criteria
This trial is for people over 8 years old with sickle cell disease who need regular blood transfusions and have developed anti-D antibodies. They must have an RH genotype that suggests D+ expression. Those with rare RH genotypes or other immune responses preventing enough safe RBC units are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive D+ RH genotype matched RBCs at the first transfusion study visit, with subsequent units provided per clinical standard of care
Follow-up
Participants are monitored for safety and effectiveness after treatment, specifically for anti-D reappearance and hemolysis
Treatment Details
Interventions
- D+ RH genotype matched red cell units
D+ RH genotype matched red cell units is already approved in United States, Canada, European Union for the following indications:
- Sickle Cell Disease
- Sickle Cell Disease
- Sickle Cell Disease
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital of Philadelphia
Lead Sponsor
New York Blood Center
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator